Avidity Partners Management LP Neurocrine Biosciences Inc Transaction History

Avidity Partners Management LP

$445 Million
Q1 2025

A detailed history of Avidity Partners Management LP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Avidity Partners Management LP holds 85,700 shares of NBIX stock, worth $10.7 Million. This represents 2.13% of its overall portfolio holdings.

Number of Shares

85,700

Previous 220,400 61.12%

Holding current value

$10.7 Million

Previous $30.1 Million 68.49%

% of portfolio

2.13%

Previous 3.4%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$107.22 - $153.29 $14.4 Million - $20.6 Million	-134,700 Reduced 61.12%	85,700 $9.48 Million
Q4 2024 Feb 14, 2025	SELL	$111.62 - $139.44 $26.7 Million - $33.4 Million	-239,600 Reduced 52.09%	220,400 $30.1 Million
Q3 2024 Nov 14, 2024	SELL	$114.58 - $153.15 $3.55 Million - $4.75 Million	-31,000 Reduced 6.31%	460,000 $53 Million
Q2 2024 Aug 14, 2024	SELL	$130.86 - $143.19 $5.95 Million - $6.52 Million	-45,500 Reduced 8.48%	491,000 $67.6 Million
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $15.8 Million - $17.5 Million	-121,500 Reduced 18.47%	536,500 $74 Million
Q4 2023 Feb 14, 2024	BUY	$106.07 - $132.76 $625,813 - $783,284	5,900 Added 0.9%	658,000 $86.7 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $1.24 Million - $1.55 Million	-13,216 Reduced 1.99%	652,100 $73.4 Million
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $13.5 Million - $15.8 Million	-150,384 Reduced 18.44%	665,316 $62.7 Million
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $90.8 Million - $119 Million	-964,300 Reduced 54.17%	815,700 $82.6 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $8.08 Million - $9.62 Million	-75,700 Reduced 4.08%	1,780,000 $213 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $35.7 Million - $41.8 Million	388,100 Added 26.44%	1,855,700 $197 Million
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $23.3 Million - $30.8 Million	307,600 Added 26.52%	1,467,600 $143 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $7.25 Million - $9.48 Million	-100,000 Reduced 7.94%	1,160,000 $109 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $32.7 Million - $43.7 Million	411,100 Added 48.43%	1,260,000 $107 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $14.5 Million - $16.6 Million	167,900 Added 24.65%	848,900 $81.4 Million
Q2 2021 Aug 16, 2021	BUY	$89.43 - $102.27 $14.3 Million - $16.3 Million	159,600 Added 30.61%	681,000 $66.3 Million
Q1 2021 May 17, 2021	BUY	$87.57 - $119.4 $19.4 Million - $26.4 Million	221,400 Added 73.8%	521,400 $50.7 Million
Q4 2020 Feb 16, 2021	BUY	$86.91 - $108.33 $26.1 Million - $32.5 Million	300,000 New	300,000 $28.8 Million
Q3 2020 Nov 16, 2020	SELL	$96.16 - $135.15 $17.8 Million - $25 Million	-185,100 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $7.41 Million - $11.4 Million	87,100 Added 88.88%	185,100 $22.6 Million
Q1 2020 Jun 17, 2020	BUY	$75.11 - $113.76 $7.36 Million - $11.1 Million	98,000 New	98,000 $8.48 Million
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $2.48 Million - $3.75 Million	-33,000 Closed	0 $0
Q4 2019 Jun 17, 2020	BUY	$86.8 - $118.57 $2.86 Million - $3.91 Million	33,000 New	33,000 $3.55 Million

Others Institutions Holding NBIX

# of Institutions

649

Shares Held

97.1M

Call Options Held

749K

Put Options Held

553K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Avidity Partners Management LP with notifications on news.

Account

Avidity Partners Management LP Neurocrine Biosciences Inc Transaction History